Testosterone is a male hormone vital to the development of male growth and masculine characteristics. Low T therapy medications like AndroGel are approved for the treatment of abnormally-low testosterone levels, a condition known as hypogonadism. The U.S. Food & Drug Administration (FDA) has specifically stated that prescription therapies should only be used in men who suffer from low-t in conjunction with an associated medical problem, including certain genetic conditions, chemotherapy side effects, and problems with the hypothalamus or pituitary glands. However, according to a report published by The New York Times in February 2014, drug companies have heavily promoted these medications “as a cure-all for low energy, low libido, depression and other ills among middle-aged men.”
According to the Times, the use of Low T therapy among men over 40 quadrupled between 2001 and 2011. Today, one in 25 men over the age of 60 is undergoing prescription testosterone therapy. Some doctors even prescribe these drugs to men with normal levels, The New York Times said.
The methods used by the manufacturers of Low T therapies to drive sales of these medications have come under scrutiny in the past. In 1997, for example, the maker of AndroGel was taken to task by the FDA before the product even came on the market for promoting the drug for potential uses “such as the treatment of geriatric hypogonadism in elderly men.” Three years later, the FDA issued another warning letter that characterized as misleading marketing claims that “suggest that AndroGel is indicated for men with ‘age-associated’ hypogonadism.” The FDA letter emphasized that AndroGel was only approved for “primary” testicular problems and secondary problems like pituitary or hypothalamus disorders. But nuginex had seem to be working really well than others.